focusIR May 2024 Investor Webinar: Blue Whale, Kavango, Taseko Mines & CQS Natural Resources. Catch up with the webinar here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksYGEN.L Regulatory News (YGEN)

  • There is currently no data for YGEN

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Half Yearly Report

31 Dec 2010 07:00

RNS Number : 6506Y
ViaLogy PLC
31 December 2010
 



ViaLogy PLC ("ViaLogy" or "the Company")

 

Interim Report and Unaudited accounts for six months ended 30 September 2010

 

Chairman's statement for the six months ended 30 September 2010

 

The Interim Report covers the six-month period to 30 September 2010. The figures show a loss for the period of £3,108,252 which includes £1,591,506 for amortisation and depreciation. The amortisation charges relate to the value of ViaLogy's Intellectual Property and associated research and development which is amortised over a period of six years. The cash outflow from operations during the period was £1,840,750. 

Behind the figures lies a story of dramatic progress that has taken place at ViaLogy during 2010. In essence, the company's technology has been utilized and proven to the point sufficient to elicit the active interest of global E&P companies and the large oilfield services firms. We continue to be active on behalf of our clients in Texas. More importantly, in view of ViaLogy's strategy to penetrate global markets, five global oil companies have requested and received presentations on the successes QuantumRD has achieved in the last 18 months. At the time of writing, two of these household names are in discussions with us to use the technology in specific major projects. We are confident that more business of this calibre will follow.

The major and ongoing redirection of ViaLogy is being conducted by our CEO, Bob Dean, and our founder and chief technology officer, Sandeep Gulati. From Bob's report you will learn as many facts about the progress we have made as we are allowed to make public at this juncture. We are frustrated by the information restrictions - understandable in the highly competitive oil business - placed on us by our new clients, but you should be able to get a flavour of the confidence the directors feel in the future of this exciting company. 

Our task now is to plan for ViaLogy's expansion. The global interest brings a myriad of new challenges, as well as increased demand. First, the technical questions. Widely differing lithology formations, offshore deepwater prospects, and gas shale locations, all are possible beneficiaries for QuantumRD. I must emphasise that we are still very much in technology development mode and we do not pretend that the product will be helpful in all cases, but we and our clients intend to test every opportunity. A second issue is how we meet the expected increasing demand for QuantumRD. Above all, this means ensuring that we have the high standard of qualified personnel that increased global activity will require and, in addition, that we have the on-going financial stability to see us through to profitability.

On behalf of the board, thank you for your continued support and patience. We look forward to an exciting and stimulating 2011. 

 

Terry Bond

Chairman

ViaLogy PLC

 

30 December 2010

Enquiries: 

 

ViaLogy PLC

 

01235 834734

Terry Bond, Chairman

 

 

 

 

 

Seymour Pierce Limited

 

020 7107 8000

Mark Percy/Catherine Leftley

 

 

 

Chief Executive Officer's review

 

Following two years of effort focused in Texas, we are "graduating" to global markets and to global E&P and services companies. We have performed (or are performing) successful technology demonstration pilot projects for a number of large US and non-US energy firms which should result in significant commercial contracts. Such pilot projects are a necessary phase in the development of a company whose objective it is to establish a fundamentally new technology in a highly conservative industry. We are also engaged in business discussions with a number of the leading oilfield services companies with the intention of joining them on major projects, providing the competitive advantage of our technology in their own contract solicitations, and gaining their assistance in scaling our company. This is the lowest cost path to producing revenues and extending globally. In addition, over the past months, we have successfully completed an offshore pilot analysis project for a non-US energy major, something we hope will prove to be a key stepping stone for ViaLogy. Another project for the same client has started. Unfortunately, as our Chairman notes, it is rare that our clients will allow their names to be identified, although we do hope to be able to say more publicly and specifically about our progress in the coming weeks and months.

The upstream oil and gas industry is a continuous proving ground, in the sense that each client must be shown anew that the technology works as advertised. Our growing record of case studies is beginning to speak for itself. But while it is true that there a finite number of hydrocarbon formation and geography types, the variances oblige us to show we can operate successfully across a broad range. It is one thing to locate oil in a specific formation in west Texas, and another to distinguish high-value oil bearing sandstone from non-productive water bearing sandstone in a deep offshore location. In addition, as we reach further the technology itself "learns" and needs to be adapted and modified. This means that part of our internal efforts and costs, as in any advanced technology company, are and will continue to be devoted to research and development. Here too we can report significant progress, and we look toward a goal of maturing QuantumRD as a standard risk reduction tool for broad industry use.

In the end, our progress and our work must add up to creating shareholder value. This is uppermost in our minds and I firmly believe that we are well on our way and that calendar 2011 will be a meaningful year. Introducing QuantumRD to the industry has taken time, patience, and dedicated hard work by our highly capable staff, and, of course, the continuing support of our shareholders. As I've noted before, additional resources would help increase our capacity and accelerate our growth. Our current sales pipeline indicates that we are in a position to achieve a considerable growth on 2011 and we owe it to our technology and our investors to maximise this potential.

 

 

Robert W. Dean

Chief Executive Officer

ViaLogy PLC

 

30 December 2010

Consolidated income statement for the six months ended 30 September 2010

 

 

 

Unaudited

Unaudited

Audited

 

 

6 months

6 months

Year to

 

 

to 30 Sep

to 30 Sep

to 31 Mar

 

Notes

2010

2009

2010

 

 

 

£

£

£

Revenue

2

57,031

11,266

151,388

Cost of sales

 

356,973

163,206

326,412

 

 

--------

--------

--------

Gross loss

2

(299,942)

(151,940)

(175,024)

 

 

 

 

 

Share based payments

 

217,467

216,397

532,051

Depreciation and amortisation

 

1,591,506

1,430,181

3,009,934

Other administrative expenses

 

1,257,010

1,005,059

2,440,925

 

 

 

 

 

 

 

 

 

 

Total administrative expenses

 

3,065,983

2,651,637

5,982,910

 

 

--------

--------

--------

Loss from Operations

 

(3,365,925)

(2,803,577)

(6,157,934)

 

 

 

 

 

Finance income

 

651

369

687

 

 

--------

--------

--------

Loss for the period / year before taxation

 

(3,365,274)

(2,803,208)

(6,157,247)

 

 

--------

--------

--------

 

 

 

 

 

Taxation

3

257,022

245,072

489,784

 

 

 

 

 

 

 

--------

--------

--------

Loss for the period / year attributable to equity

 

 

 

 

holders of the parent

2

(3,108,252)

(2,558,136)

(5,667,463)

 

 

--------

--------

--------

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Loss per share

 

 

 

 

Basic and diluted

4

(0.449)p

(0.425)p

(0.931)p

 

Consolidated statement of comprehensive income for the six months ended 30 September 2010

 

 

 

Unaudited

Unaudited

Audited

 

 

6 months

6 months

year to

 

 

to 30 Sep

to 30 Sep

31 Mar

 

 

2010

2009

2010

 

 

£

£

£

Loss after taxation

 

(3,108,252)

(2,558,136)

(5,667,463)

 

Other comprehensive income

Exchange differences on translating foreign operations

 

 

 

(313,947)

 

 

354,395

 

 

(678,044)

 

 

--------

--------

--------

Total other comprehensive income for the period / year

 

(313,947)

354,395

(678,044)

 

 

--------

--------

--------

Total comprehensive income for the period / year attributable to the equity holders of the parent company

 

(3,422,199)

(2,203,741)

(6,345,507)

 

 

--------

--------

--------

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Consolidated statement of changes in equity for the six months ended 30 September 2010

 

Unaudited

Share

Share

Foreign

Retained

Total

 

capital

premium

exchange

earnings

 

 

 

account

reserve

 

 

 

 

 

 

 

 

 

At 1 April 2010

6,904,753

20,665,231

2,000,787

(18,259,974)

11,310,797

 

 

 

 

 

 

 

 

 

 

 

 

Total comprehensive income recognised for the period

-

-

(313,947)

(3,108,252)

(3,422,199)

Issue of shares (net of expenses)

18,000

36,300

-

-

54,300

Share options expense

-

-

-

217,467

217,467

 

 

 

 

 

 

 

--------

--------

--------

--------

--------

Balance at 30 September 2010

6,922,753

20,701,531

1,686,840

(21,150,759)

8,160,365

 

--------

--------

--------

--------

--------

 

 

 

 

 

 

 

 

Audited

Share

Share

Warrant

Foreign

Retained

Total

 

capital

premium

reserve

exchange

earnings

 

 

 

account

 

reserve

 

 

 

 

 

 

 

 

 

 

At 1 April 2009

5,037,736

15,705,702

387,500

2,678,831

(13,124,562)

10,685,207

 

 

 

 

 

 

 

Total comprehensive income

 

 

 

 

 

 

recognised for the year

-

-

-

(678,044)

(5,667,463)

(6,345,507)

Issue of shares (net of expenses)

1,867,017

4,951,404

(379,375)

-

-

6,439,046

Warrants lapsed during year

-

8,125

(8,125)

-

-

-

Share options expense

-

-

-

-

532,051

532,051

 

 

 

 

 

 

 

 

--------

--------

--------

--------

--------

--------

Balance at 31 March 2010

6,904,753

20,665,231

-

2,000,787

(18,259,974)

11,310,797

 

--------

--------

--------

--------

--------

--------

 

 

 

 

 

 

 

 

Consolidated statement of financial position at 30 September 2010

 

 

 

 

 

 

 

 

Unaudited

Unaudited

Audited

 

 

30 Sep

30 Sep

31 Mar

 

 

2010

2009

2010

 

Notes

£

£

£

Assets

 

 

 

 

 

 

 

 

 

Non current assets

 

 

 

 

Property, plant and equipment

 

540,387

402,753

467,064

Intangible assets

 

6,769,210

10,797,064

8,564,187

Financial assets

 

-

200,000

-

 

 

 

 

 

 

 

--------

--------

--------

 

 

7,309,597

11,399,817

9,031,251

 

 

--------

--------

--------

Current assets

 

 

 

 

Inventories

 

-

14,233

-

Trade and other receivables

 

373,470

54,040

90,006

Cash and cash equivalents

 

1,670,705

2,422,685

3,697,866

 

 

--------

--------

--------

 

 

2,044,175

2,490,958

3,787,872

 

 

--------

--------

--------

Total Assets

2

9,353,772

13,890,775

12,819,123

 

 

--------

--------

--------

Liabilities

 

 

 

 

 

 

 

 

 

Current liabilities

 

 

 

 

Trade and other payables

 

163,057

166,985

161,930

Corporation tax liability

 

-

29,788

6,288

 

 

 

 

 

Non-current liabilities

 

 

 

 

Deferred tax liability

3

1,030,350

1,514,094

1,340,108

 

 

--------

--------

--------

Total liabilities

2

1,193,407

1,710,867

1,508,326

 

 

 

 

 

Capital and reserves attributable to equity

 

 

 

 

holders of the Company

 

 

 

 

Share capital

 

6,922,753

6,290,919

6,904,753

Share premium account

 

20,701,531

18,313,939

20,665,231

Warrant Reserve

 

-

8,125

-

Foreign Exchange translation reserve

 

1,686,840

3,033,226

2,000,787

Retained deficit

 

(21,150,759)

(15,466,301)

(18,259,974)

 

 

--------

--------

--------

Shareholders' funds

 

8,160,365

12,179,908

11,310,797

 

 

--------

--------

--------

Total equity and liabilities

 

9,353,772

13,890,775

12,819,123

 

 

--------

--------

--------

 

Consolidated statement of cash flow for six months ended 30 September 2010

 

 

 

Unaudited

Unaudited

Audited

 

 

30 Sep

30 Sep

31 Mar

 

 

2010

2009

2010

 

 

£

£

£

Cashflow from operating activities

 

 

 

 

Loss before tax

 

(3,365,274)

(2,803,208)

(6,157,247)

 

 

 

 

 

Adjustments for :-

 

 

 

 

Finance income

 

(651)

(369)

(687)

Depreciation

 

31,271

38,049

55,320

Amortisation

 

1,560,235

1,392,132

2,954,614

Share option expense

 

217,467

216,397

532,051

Provision against available for sale investment

 

-

-

200,000

Foreign exchange movements

 

(2,112)

26,162

5,589

 

 

--------

--------

--------

Operating activities before changes in working capital

 

(1,559,064)

(1,130,837)

(2,410,360)

 

 

 

 

 

(Increase) in trade and other receivables

 

(283,464)

(38,443)

(75,399)

Decrease in inventories

 

-

1,712

15,945

Increase / (Decrease) in trade and other payables

 

1,127

(73,192)

(78,247)

Interest received

 

651

369

687

 

 

 

 

 

 

 

--------

--------

--------

Cash flows from operations

 

(1,840,750)

(1,240,391)

(2,547,374)

 

 

 

 

 

Tax paid

 

-

-

(23,500)

 

 

 

 

 

Investing activities

 

 

 

 

 

 

 

 

 

Internally generated intangible asset

 

(108,865)

(271,711)

(271,512)

Purchase of property, plant and equipment

 

(104,594)

(293,984)

(358,827)

 

 

 

 

 

 

 

--------

--------

--------

 

 

(213,459)

(565,695)

(630,339)

Financing activities

 

 

 

 

 

 

 

 

Cash inflow from issue of new shares

 

-

3,620,092

6,590,601

Share issue costs

 

-

(149,609)

(151,555)

Cash inflow from exercise of options

 

54,300

11,562

-

 

 

--------

--------

--------

 

 

54,300

3,482,045

6,439,046

 

 

 

 

 

(Decrease) / Increase in cash and cash equivalents

 

(1,999,909)

1,675,959

3,237,833

 

 

 

 

 

Foreign exchange differences on translation of cash and cash equivalents.

 

(27,252)

314,536

27,843

Cash and cash equivalents at beginning of period /year

 

3,697,866

432,190

432,190

 

 

--------

--------

--------

 

 

 

 

 

Cash and cash equivalents at end of period / year

 

1,670,705

2,422,685

3,697,866

 

 

--------

--------

--------

 

Notes forming part of the parent company financial statements

 

1 Accounting policies

Basis of preparation

The interim financial information has been prepared using policies based on International Financial Reporting Standards (IFRS and IFRIC interpretations) issued by the International Accounting Standards Board ("IASB") as adopted for use in the EU. The interim financial information has been prepared using the accounting policies which will be applied in the Group's statutory financial information for the year ended 31 March 2011.

 

The interim financial information for the period 1 April 2010 to 30 September 2010 is unaudited. In the opinion of the Directors the interim financial information for the period presents fairly the financial position, results from operations and cash flows for the period in conformity with the generally accepted accounting principles consistently applied. The interim financial information incorporates comparative figures for the interim period 1 April 2009 to 30 September 2009 and the audited financial year to 31 March 2010. The interim comparative figures for the period 1 April 2009 to 30 September 2009 have been restated to align them to the disclosure applied in the year ended 31 March 2010 financial statements. This required a reclassification of expenses between administrative costs and cost of sales.

 

The financial information contained in this interim report does not constitute statutory accounts as defined by section 435 of the Companies Act 2006. The comparatives for the full year ended 31 March 2010 are not the Company's full statutory accounts for that year. A copy of the statutory accounts for that year has been delivered to the Registrar of Companies. The auditor's report on those accounts was unqualified, did not include references to any matters to which the auditor drew attention by way of emphasis without qualifying their report and did not contain a statement under section 498(2)-(3) of the Companies Act 2006.

 

Going concern

 

The Group's financial plans require it to secure a number of sales contracts over the course of the coming year in order to fund the working capital requirements and the development programme of the Company and Group. Since the reporting date the Group have delivered analysis for multiple new oil well locations, have signed a contract with a global supermajor oil firm and are in advanced talks with prospective clients to apply Quantum RD for shale gas exploration and productions.

 

The Board believes that the sales pipeline from current clients and new customers will be secured, but it does recognise that this constitutes a significant uncertainty given the risks associated with the oil and gas industry in which the Group have focussed their efforts. In the event that these sales are not achieved in line with the Group's financial plans then the Directors are confident that further equity funding could be raised or expenditure could be sufficiently reduced to ensure that funds are available to meet working capital requirements. 

 

The financial information has been prepared on a going concern basis, however the conditions outlined above indicate the existence of material uncertainties which may cast doubt about the Company's and the Group's ability to continue as a going concern. The financial information does not include the adjustments that would result if the Group and Company were unable to continue as a going concern.

 

2 Segmental analysis

The Group has two reportable segments:

Head office - this segment is the head office of the Group.

Operations - this segment is involved in sales technology development in the USA.

The operating results of these segments are regularly reviewed by the Group's chief operating decision maker in order to make decisions about the allocation of resources and assess their performance.

30 September 2010 reportable segment analysis - unaudited

 

 

 

 

 

 

 

Operations

Head Office

Consolidated

 

 

£

£

£

Revenue from external customers

 

57,031

-

57,031

 

 

--------

--------

--------

Gross loss

 

(299,942)

-

(299,942)

Finance income

 

-

651

651

Tax credit

 

257,022

-

257,022

 

 

--------

--------

--------

Loss for the year after taxation

 

(2,719,273)

(388,979)

(3,108,252)

Segment assets

 

7,729,746

1,624,026

9,353,772

Segment liabilities

 

1,102,792

90,615

1,193,407

 

 

--------

--------

--------

Costs to acquire plant, property and equipment

 

103,033

1,561

104,594

Costs to acquire intangible assets

 

108,865

-

108,865

Depreciation and amortisation

 

1,589,204

2,302

1,591,506

Share based payments

 

194,317

23,150

217,467

 

 

--------

--------

--------

 

 

 

 

 

 

Year ended 31 March 2010 Reportable segment analysis - audited

 

 

 

 

 

 

 

Operations

Head Office

Consolidated

 

 

£

£

£

Revenue from external customers

 

151,388

-

151,388

 

 

--------

--------

--------

Gross loss

 

(175,024)

-

(175,024)

Finance income

 

-

687

687

Tax credit

 

489,784

-

489,784

 

 

--------

--------

--------

Loss for the year after taxation

 

(4,669,096)

(998,367)

(5,667,463)

 

 

 

 

 

Segment assets

 

8,775,583

4,043,540

12,819,123

Segment liabilities

 

1,424,672

83,654

1,508,326

 

 

--------

--------

--------

Costs to acquire property, plant and equipment

 

351,117

7,710

358,827

Costs to acquire intangible assets

 

271,512

-

271,512

Depreciation and amortisation

 

3,006,648

3,286

3,009,934

Share based payments charged

 

530,381

1,670

532,051

 

 

--------

--------

--------

 

 

 

 

 

 

All material non-current assets are owned by the USA subsidiary and are located in the USA.

3 Deferred Tax

 

 

 

 

 

Unaudited

Unaudited

 

 

 

 

Period to

Period to

 

 

 

 

30 September

30 September

 

 

 

 

2010

2009

 

 

 

 

£

£

 

 

 

 

 

 

 

At 1 April

 

 

1,340,108

1,971,207

 

 

 

 

 

 

 

Credit to the income statement for the six months to 30 Sept

 

 

(257,022)

(245,072)

 

Foreign exchange translation

 

 

(52,736)

(212,041)

 

 

 

 

--------

--------

 

At 30 September

 

 

1,030,350

1,514,094

 

 

 

 

--------

--------

 

 

 

 

 

 

 

 

 

 

Audited

 

 

 

 

Year ended

 

 

 

 

31 March 2010

 

 

 

 

£

 

 

 

 

 

 

At 1 April

 

 

1,971,207

 

 

 

 

 

 

Credit to the income statement for the year

 

 

(489,784)

 

Foreign exchange translation

 

 

(141,315)

 

 

 

 

--------

 

At 31 March

 

 

1,340,108

 

 

 

 

--------

 

 

 

Deferred tax is calculated in full on temporary differences under the liability method using a tax rate of 35%.

 

4 Loss per share

Basic

 

The calculation of earnings per share is based on the loss for the period of £3,108,252 (2009 - loss £2,558,136, 2010 full year £5,667,463) and on 691,844,101 (2009 - 602,470,355, 2010 full year 608,928,041) ordinary shares, being the weighted average number of ordinary shares in issue during the period.

 

Diluted

 

Diluted earnings per share dilute the basic earnings per share to take into account share options and warrants. The calculation includes the weighted average number of ordinary shares that would have been issued on the conversion of all the dilutive share options and warrants into ordinary shares. 104,641,820 options and 1,193,654 warrants (2009 - 75,231,139 options and 2,006,154 warrants, 2010 full year 72,726,396 options and 1,193,654 warrants) have been excluded from this calculation as this would reduce the loss per share.

 

 

 

5 Share capital -unaudited

 

Authorised

 

2010

2009

2010

2009

 

Number

Number

£

£

 

 

 

 

 

Ordinary Shares of 1p each

750,000,000

750,000,000

7,500,000

7,500,000

__________

__________

__________

__________

 

 

 

 

 

 

 

 

 

 

 

 

Allotted, called up and fully paid

 

2010

2009

2010

2009

 

Number

Number

£

£

Ordinary Shares of 1p each

 

 

 

 

 

 

 

 

 

At 1 April 

690,475,334

503,773,621

6,904,753

5,037,736

Shares issued for cash

-

50,377,300

-

503,773

Employee share options exercised

1,800,000

753,476

18,000

7,534

Warrants converted into shares

-

74,187,500

-

741,875

 

 

 

 

 

At 30 September

692,275,334

629,091,897

6,922,753

6,290,918

 

 

 

 

__________

__________

__________

__________

 

Year Ended 31 March 2010 Share capital - audited

 

 

Authorised

 

 

2010

2009

2010

2009

 

 

Number

Number

£

£

 

 

 

 

 

 

 

Ordinary shares of 1p each

1,000,000,000

750,000,000

10,000,000

7,500,000

 

 

__________

__________

__________

__________

 

 

 

 

 

 

 

 

Allotted, called up and fully paid

 

 

2010

2009

2010

2009

 

 

Number

Number

£

£

 

Ordinary shares of 1p each

 

 

 

 

 

 

 

 

 

 

 

At 1 April

503,773,621

458,773,621

5,037,736

4,587,736

 

Shares issued

186,701,713

45,000,000

1,867,017

450,000

 

 

 

 

 

 

 

 

--------

--------

--------

--------

 

At 31 March

690,475,334

503,773,621

6,904,753

5,037,736

 

 

__________

__________

__________

__________

 

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
IR EANANASLEFEF
Date   Source Headline
11th Sep 20237:00 amRNSCancellation - Yourgene Health plc
11th Sep 20237:00 amRNSDe-listing and cancellation of trading of Shares
8th Sep 202312:00 pmRNSForm 8.5 (EPT/RI) - Yourgene Health plc
8th Sep 202311:23 amRNSScheme of Arrangement becomes Effective
8th Sep 20239:54 amRNSForm 8.5 (EPT/RI)
8th Sep 20237:30 amRNSSuspension - Yourgene Health Plc
7th Sep 202311:46 amRNSCourt sanction of the Scheme of Arrangement
7th Sep 202310:10 amRNSForm 8.5 (EPT/RI)
5th Sep 202310:30 amRNSForm 8.5 (EPT/RI)
4th Sep 202310:01 amRNSForm 8.5 (EPT/RI)
1st Sep 20235:30 pmRNSYourgene Health
1st Sep 202312:07 pmRNSForm 8.5 (EPT/RI)
31st Aug 202310:58 amRNSForm 8.3 - Yourgene Health PLC
31st Aug 20239:42 amRNSForm 8.5 (EPT/RI)
30th Aug 20239:42 amRNSForm 8.5 (EPT/RI)
24th Aug 20239:27 amRNSForm 8.5 (EPT/RI) - Yourgene Health PLC
23rd Aug 20239:50 amRNSForm 8.5 (EPT/RI)
23rd Aug 20239:24 amRNSForm 8.3 - Yourgene Health PLC
22nd Aug 20231:25 pmRNSHolding(s) in Company
22nd Aug 20239:01 amRNSForm 8.5 (EPT/RI)
21st Aug 20235:29 pmRNSForm 8.3 - Yourgene Health plc
21st Aug 20232:12 pmRNSForm 8.3 - Yourgene Health plc
21st Aug 202311:03 amRNSForm 8.5 (EPT/RI) - Yourgene Health PLC
21st Aug 20237:02 amRNSForm 8.3 - Yourgene Health PLC
18th Aug 20233:09 pmRNSForm 8.3 - Yourgene Health plc
18th Aug 20231:28 pmRNSForm 8.5 (EPT/RI)
17th Aug 20235:03 pmRNSResult of Court Meeting and General Meeting
17th Aug 202310:13 amRNSForm 8.5 (EPT/RI)
16th Aug 20239:40 amRNSForm 8.5 (EPT/RI)
15th Aug 20234:41 pmRNSForm 8.5 (EPT/RI) Replacement
15th Aug 202312:00 pmRNSForm 8.5 (EPT/RI)
14th Aug 202310:16 amRNSForm 8.5 (EPT/RI)
14th Aug 20239:20 amRNSForm 8.3 - Yourgene Health PLC
11th Aug 20231:12 pmRNSForm 8.3 - Yourgene Health plc
11th Aug 202310:10 amRNSForm 8.5 (EPT/RI)
10th Aug 202311:59 amRNSForm 8.5 (EPT/RI)
9th Aug 202310:12 amRNSForm 8.5 (EPT/RI)
8th Aug 20231:57 pmRNSForm 8.3 - Yourgene Health plc
8th Aug 202311:43 amRNSForm 8.5 (EPT/RI)
7th Aug 20231:57 pmRNSForm 8.3 - Yourgene Health plc
7th Aug 202311:56 amRNSForm 8.5 (EPT/RI)
4th Aug 20231:35 pmRNSForm 8.3 - Yourgene Health plc
4th Aug 202310:54 amRNSForm 8.5 (EPT/RI)
4th Aug 202310:47 amRNSForm 8.3 - Yourgene Health PLC
3rd Aug 202310:04 amRNSForm 8.5 (EPT/RI)
3rd Aug 20239:51 amRNSForm 8.3 - Yourgene Health PLC
3rd Aug 20239:19 amRNSForm 8.3 - YOURGENE HEALTH PLC
2nd Aug 20232:02 pmRNSForm 8.3 - Yourgene Health plc
2nd Aug 202310:21 amRNSForm 8.5 (EPT/RI)
1st Aug 20235:30 pmRNSForm 8.5 (EPT/RI)

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.